Here, we report results from the Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study, which was a prospective, multicenter observational study designed to validate fibulin-3 and SOMAscan and benchmark performance against mesothelin, which has been widely studied but offers only 32% sensitivity at 95% specificity.10 This evidence concerns the gene EFEMP1 and mesothelioma.